Credit Analyst Surprise in Boston Scientific (BSX)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A surprising ratings agency call is helping Boston Scientific Corp. (NYSE: BSX) after the company made a debt issuance filing.   As Boston Scientific is (and has been for ages) a turnaround which hasn’t turned around, this may be a very positive development for the company. Both Fitch and Moody’s have kept Boston Scientific in junk territory after the proposed issuance of $1 billion in unsecured notes.  Fitch has given the company a rating of “BB+” with a positive outlook and while Moody’s rated these new notes “Ba1” with a stable outlook.  Standard & Poor’s is the standout call today as its call takes Boston Scientific out of junk status.  The new “investment grade” rating is “BBB-” for its corporate credit rating and for the unsecured notes.

S&P noted that Boston Scientific has continued to maintain or grow share in its key markets, while generating strong cash flows and paying down debt leverage with staggering out debt tranches.  S&P noted that the bond traunches filed will be issued in 5-year and 10-year maturities.  S&P did note that this leaves $2.6 billion in obligations remaining that need to be refinanced or paid off after this $1 billion refinancing.

S&P also believes that the company will continue to make progress on its debt refinancings well ahead of the 2011 maturities and believes that product diversity will generate revenue and cash flow growth even if there are setbacks in a product line.  International sales are about 42% of revenues and the cardiac rhythm management accounted for 31% and cardiovascular group represented 43% of sales in the first three quarters of 2009.

S&P has put the outlook now at “stable” after it had been at positive.  The other ratings agencies having a positive bias leaves the door open for a Moody’s and/or fFitch upgrade in the coming months.  That would make the company’s debt and corporate credit rating “investment grade” at the other agencies as well if those positive outlooks turn into formal upgrades.

Boston Scientific shares are trading up 2% at $8.65, and is 52-week trading range is $6.08 to $11.77.

JON C. OGG

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618